New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, ...

Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...

In 2024, the sale of antidepressant drugs in Russia increased by 20%, reaching 16.1 million packages by November, according ...

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII ...

Johnson & Johnson announced the U.S. FDA approval of a supplemental New Drug Application for Spravato CIII nasal spray, making this ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Brexpiprazole is used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults, ...

They suggest other fast-acting antidepressants could offer a competitive challenge to J&J's drug, including Axsome Therapeutics' recently approved Auvelity (bupropion/dextromethorphan), Sage ...

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

In 2024, the sale of antidepressants in Russia reached a record level, increasing by 20 percent compared to the previous year ...

Alembic Pharmaceuticals has received USFDA approval for its generic version of Brexpiprazole tablets, used to treat major ...

Authoritative and well-researched, Chemically Imbalanced documents the overinflation of antidepressant efficacy, where the ...